- Home
- CPZ vs DMAC Comparison
CPZ vs DMAC Comparison
Compare CPZ & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPZ
- DMAC
- Stock Information
- Founded
- CPZ 2019
- DMAC 2000
- Country
- CPZ United States
- DMAC United States
- Employees
- CPZ N/A
- DMAC N/A
- Industry
- CPZ Trusts Except Educational Religious and Charitable
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CPZ Finance
- DMAC Health Care
- Exchange
- CPZ Nasdaq
- DMAC Nasdaq
- Market Cap
- CPZ 298.2M
- DMAC 321.5M
- IPO Year
- CPZ N/A
- DMAC N/A
- Fundamental
- Price
- CPZ $15.03
- DMAC $7.37
- Analyst Decision
- CPZ
- DMAC Strong Buy
- Analyst Count
- CPZ 0
- DMAC 4
- Target Price
- CPZ N/A
- DMAC $15.50
- AVG Volume (30 Days)
- CPZ 63.0K
- DMAC 390.4K
- Earning Date
- CPZ 01-01-0001
- DMAC 11-12-2025
- Dividend Yield
- CPZ 11.07%
- DMAC N/A
- EPS Growth
- CPZ N/A
- DMAC N/A
- EPS
- CPZ N/A
- DMAC N/A
- Revenue
- CPZ N/A
- DMAC N/A
- Revenue This Year
- CPZ N/A
- DMAC N/A
- Revenue Next Year
- CPZ N/A
- DMAC N/A
- P/E Ratio
- CPZ N/A
- DMAC N/A
- Revenue Growth
- CPZ N/A
- DMAC N/A
- 52 Week Low
- CPZ $13.17
- DMAC $3.19
- 52 Week High
- CPZ $16.11
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- CPZ 29.00
- DMAC 60.01
- Support Level
- CPZ $15.06
- DMAC $5.26
- Resistance Level
- CPZ $15.34
- DMAC $6.47
- Average True Range (ATR)
- CPZ 0.24
- DMAC 0.52
- MACD
- CPZ 0.02
- DMAC 0.07
- Stochastic Oscillator
- CPZ 31.56
- DMAC 96.23
About CPZ Calamos Long/Short Equity & Dynamic Income Trust
Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.